Financial insights of ODYY

MyFinsight

For the quarter ending 2026-01-31.

Income Statement	2026-01-31	2025-10-31	2025-07-31
Research and development expense	-	-	0*
General and administrative expense	181,942	303,190	255,188.25*
Loss from operations	-181,942	-303,190	-255,188.25*
Gain on sale of product candidates and related assets	-	-	0*
Impairment of investment in preferred stock of oragenics, inc	-	-	0*
Loss from change in fair value of oragenics, inc. common stock	0	0	-114,854.25*
Interest expense	412,429	95,336	63,129*
Financing costs	2,572,655	507,368	-
Change in fair value of derivative liability	-	422,419	-
Change in fair value of derivative liabilities	-424,348	-	-
Other expense, net	-10,249	28	-2,501.25*
Net loss attributable to common shareholders	-3,601,623	-483,447	-435,672.75*
Deemed dividend	-	-	0*
Net loss attributable to common stockholders	-	-	-435,672.75

Basic EPS	-0.03	0	-0.004
Diluted EPS	-0.03	0	-0.004
Basic Average Shares	107,853,763	106,036,632	104,709,763
Diluted Average Shares	107,853,763	106,036,632	104,709,763